Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 | AVESİS

Istanbul University Research Information System

Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4

Copy For Citation

Bachelot T., Royce M., Villanueva C., Melo Cruz F., Hegg R., Falkson C., ...More

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28

Publication Type: Conference Paper / Summary Text
Volume: 28
City: Madrid
Country: Spain
Istanbul University Affiliated: Yes